11 Greenway Plaza,Suite 1000
Houston , TX, 77046-1173

Rank

Rank Universe
28 32

Summary

The fund seeks capital appreciation in the long term by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests in securities of issuers engaged primarily in health care-related industries, More

Link

Directors

Jan 16, 2024
  • Beth Ann Brown
  • Cynthia Hostetler
  • Eli Jones
  • Robert C. Troccoli
  • Teresa M. Ressel
  • Elizabeth Krentzman
  • Daniel S. Vandivort
  • Anthony J. LaCava, Jr.
  • Martin L. Flanagan
  • Joel W. Motley
  • Prema Mathai-Davis

Chief Compliance Officer

  • Todd F. Kuehl

Fund Manager(s)

Price

  • $ 38.1 ( -0.06 )
    Dec 17, 2024
    Last Close
  • Net Assets
  • $1.3B
    Mar 28, 2024
  • Holding
  • 80
    Sep 27, 2024
    More

  • 52-Week High/Low
  • $44.52 - $36.13
  • Turnover
  • 44%
  • Expense Ratio
  • 0.81%

Company Name

Holding

Eli Lilly and Co. 8.5 %
Boston Scientific Corp. 5.8 %
UnitedHealth Group Inc. 5.23 %
McKesson Corp. 4.28 %
Danaher Corp. 4.24 %
Vertex Pharmaceuticals Inc. 3.89 %
Intuitive Surgical, Inc. 3.82 %
Merck & Co., Inc. 3.72 %
AstraZeneca PLC 3.63 %
Regeneron Pharmaceuticals, Inc. 3.56 %
More 3.56 %

Documents

Prospectus

Annual Reports

Performance

YTD

-

3 Year

-5.13%

5 Year

-9.5%

Best

42.91%

2013

Worst

-13.31%

2022

Alpha

GGHYX S&P 500

Chart +